Latest Breaking News On - Applied therapeutics - Page 2 : vimarsana.com

Applied Therapeutics (APLT) to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

Short Interest in Applied Therapeutics, Inc. (NASDAQ:APLT) Decreases By 12.5%

Applied Therapeutics, Inc. (NASDAQ:APLT – Get Free Report) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 3,790,000 shares, a decline of 12.5% from the February 29th total of 4,330,000 shares. Based on an average daily volume of 2,120,000 shares, the short-interest ratio […]

Applied Therapeutics Stock (NASDAQ:APLT), Quotes and News Summary

Applied Therapeutics Stock (NASDAQ: APLT) stock price, news, charts, stock research, profile.

FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease - Applied Therapeutics (NASDAQ:APLT)

FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates a decision from EMA in Q4 2024.

FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease

What's Going to Be Hot at ACC 2024

Some eagerly awaited drug and device trials, like RELIEVE-HF and EMPACT-MI, will be unveiled at the ACC’s 75th annual meeting.

Applied Therapeutics (NASDAQ:APLT) Shares Gap Down to $6.80

Applied Therapeutics, Inc. (NASDAQ:APLT – Get Free Report)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $6.80, but opened at $6.00. Applied Therapeutics shares last traded at $6.31, with a volume of 687,581 shares trading hands. Analyst Ratings Changes Several equities research analysts recently commented on […]

Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review

Applied Therapeutics Says FDA Extends Review Period Of NDA For Govorestat

Applied Tx's pediatric rare disease prosect hits another snag